PRO DEX INC
No enriched coverage for $PDEX in the last 7 days.
No SEC Form 4 filings for $PDEX in the last 30 days.
See all $PDEX insider activity →Pro-Dex (PDEX) reported fiscal 2026 net sales of $77.55M, up 16%, and net income of $13.66M, up 52%. Medical-device sales rose 30%, while repair revenue fell 33%. The largest customer accounted for 78% of sales with a supply agreement through 2028. Operating cash flow was $7.24M, and the company repurchased 79,898 shares.
PRO DEX INC (PDEX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 16, 2026, Pro-Dex, Inc. (the “Company”) entered into a Third Amendment to Standard Industrial/Commercial Multi-Tenant Lease – Net (the “Third Amendment”) with Irvine Business Properties, a California general partn
Van Kirk Richard Lee Jr (Chief Executive Officer) sold 19,235 shares of PRO DEX INC (PDEX) at an average of $60.58 ($58.66–$64.70, $1.17M total) across 9 trades on 2026-09-09 under a Rule 10b5-1 trading plan.
Recent PDEX coverage spans earnings, corporate actions and insider activity.
Positive earnings surprise may lift the stock, but concentration risk on a single customer could limit upside.
The lease amendment has minimal immediate impact on valuation; it secures occupancy but adds modest rent expense.
Potential short‑term pressure on PDEX as insider reduces stake.
Minor insider sell by CFO; unlikely to move price materially.
Strong earnings and profit beat likely support further upside.
AlphAI scores every news story that mentions PDEX with an AI model for sentiment and relevance, and aggregates insider trades from PRO DEX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Pro-Dex (PDEX) reported fiscal 2026 net sales of $77.55M, up 16%, and net income of $13.66M, up 52%. Medical-device sales rose 30%, while repair revenue fell 33%. The largest customer accounted for 78% of sales with a supply agreement through 2028. Operating cash flow was $7.24M, and the company repurchased 79,898 shares.
2 min readPRO DEX INC (PDEX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 16, 2026, Pro-Dex, Inc. (the “Company”) entered into a Third Amendment to Standard Industrial/Commercial Multi-Tenant Lease – Net (the “Third Amendment”) with Irvine Business Properties, a California general partn
1 min readVan Kirk Richard Lee Jr (Chief Executive Officer) sold 19,235 shares of PRO DEX INC (PDEX) at an average of $60.58 ($58.66–$64.70, $1.17M total) across 9 trades on 2026-09-09 under a Rule 10b5-1 trading plan.
1 min readCharlton Alisha (Chief Financial Officer) sold 2,300 shares of PRO DEX INC (PDEX) at an average of $61.30 ($61.05–$61.76, $0.14M total) across 2 trades on 2026-09-09.
1 min readPro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
2 min readPro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.
2 min readModular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
3 min readPro-Dex (PDEX) reported Q4 2026 net sales of $20.4M, up 17% YoY, and net income of $2.9M ($0.87 per share). Full-year 2026 sales rose 16% to $77.5M, with net income at $13.7M ($4.12 per share). Growth was driven by increased revenue from a major customer's next-gen handpiece and the acquisition of APM.
2 min readPRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 FOURTH QUARTER AND FULL-YEAR RESULTS IRVINE, CA, September 3, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) t oday announced financial results for i
2 min readPRO DEX INC (PDEX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Compensation of Chief Executive Officer and Chief Financial Officer . On August 26, 2026, the Compensation Committee approv
1 min read